CNBC Pro

Teva is primed for a big bounce after years of underperformance, Barclays says

A Teva Pharmaceutical Industries building is seen in Jerusalem December 14, 2017.
Ammar Awad | Reuters

Shares for Teva Pharmaceuticals could jump 31% from here after the company settles a spate of legal issues, according to Barclays.

More In Street Calls

Analysts name the top 'high conviction' stocks for playing the market turbulence
CNBC ProAnalysts name the top 'high conviction' stocks for playing the market turbulence
Here are Friday's biggest analyst calls: Apple, Tesla, Coinbase, Domino's, Costco, Meta & more
CNBC ProHere are Friday's biggest analyst calls: Apple, Tesla, Coinbase, Domino's, Costco, Meta & more
Wedbush upgrades fuboTV to outperform citing 'compelling entry point' after stock pullback
CNBC ProWedbush upgrades fuboTV to outperform citing 'compelling entry point' after stock pullback